参考文献
1. Fiorentini A, Capelli D, Saraceni F, et al. The Time Has Come for Targeted Therapies for AML: Lights and Shadows. Oncol Ther. 2020 Jun;8(1):13-32.
2. National Cancer Institute. Surveillance, Epidemiology, and End Results (SEER) Program. National Cancer Institute; Bethesda, MD, USA: 2021.
3. Cancer Stat Facts: Leukemia—Acute Myeloid Leukemia (AML).[EB/OL]. https://seer.cancer.gov/ statfacts/html/amyl.html available at 2020.07.28.
4. 李雅,陈瑜,李军民.老年急性髓系白血病的治疗进展[J].内科理论与实践,2019,14(06): 391-394.
5. Thol F, Heuser M. Treatment for Relapsed/Refractory Acute Myeloid Leukemia. Hemasphere. 2021 Jun 1;5(6):e572.
6. Liesveld JL, et al. Acute myelogenous leukemia. In: Williams Hematology, 9th ed., Kaushansky K, et al. New York, NY: McGraw-Hill Education, 2016.
7. Kiyoi H, Kawashima N, Ishikawa Y. FLT3 mutations in acute myeloid leukemia: Therapeutic paradigm beyond inhibitor development. Cancer Sci. 2020 Feb;111(2):312-322.
8. Emadi A, et al. Acute myeloid leukemia in adults. In: Wintrobe's Clinical Hematology, 13th ed., Greer JP. et al. Philadelphia, PA: Lippincott Williams & Wilkins, 2014.
9. Fröhling S, Schlenk RF, Breitruck J, et al. AML Study Group Ulm. Acute myeloid leukemia. Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm. Blood. 2002 Dec 15;100(13):4372-4380.
10. Ravandi F, Kantarjian H, Faderl S, et al. Outcome of patients with FLT3-mutated acute myeloid leukemia in first relapse. Leuk Res. 2010 Jun;34(6):752-756.
11. NCCN Clinical Practice Guidelines in Oncology:Acute Myeloid Leukemia(Version 1.2022), 2022.
12. 中国临床肿瘤学会指南工作委员会.中国临床肿瘤学会(CSCO)恶性血液病诊疗指南2021[M].北京:人民卫生出版社,2021.
13. 中华医学会血液学分会白血病淋巴瘤学组.中国成人急性髓系白血病(非急性早幼粒细胞白血病)诊疗指南(2021年版)[J].中华血液学杂志,2021,42(08):617-623.
14. Perl AE, Altman JK, Cortes J, et al. Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: A multicentre, first-in-human, open-label, phase 1-2 study. Lancet Oncol. 2017;18:1061-1075.
15. Perl AE, Martinelli G, Cortes J, et al. Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML. N. Engl. J. Med. 2019;381:1728-1740.
16. Heuser M, Ofran Y, Boissel N, et al. Acute myeloid leukaemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020 Jun;31(6):697-712..
17. 中华医学会血液学分会白血病淋巴瘤学组.中国复发难治性急性髓系白血病诊疗指南(2021年版)[J].中华血液学杂志,2021,42(08):624-627.
18. Short NJ, DiNardo CD, Daver N, et al. A Triplet Combination of Azacitidine, Venetoclax and Gilteritinib for Patients with FLT3-Mutated Acute Myeloid Leukemia: Results from a Phase I/II Study. Blood (2021) 138 (Supplement 1):696.
19. Daver N, Altman JK, Maly J, et al. Efficacy and Safety of Venetoclax in Combination with Gilteritinib for Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia in the Expansion Cohort of a Phase 1b Study. Blood (2020) 136 (Supplement 1):20-22.
20. Pratz KW, Cherry M, Altman JK, et al. A Phase 1 Study of Gilteritinib in Combination with Induction and Consolidation Chemotherapy in Patients with Newly Diagnosed AML: Final Results. Blood (2020) 136 (Supplement 1):16-17.
21. Abuasab T, Kantarjian H, Garcia-Manero G, et al. Phase II Study of Cladribine, Idarubicin, Cytarabine (CLIA) Plus Gilteritinib in Patients with FLT3 Mutated Acute Myeloid Leukemia (AML). Blood (2021) 138 (Supplement 1):2330.
22. Wang ES, Montesinos P, Minden MD, et al. Phase 3, Open-Label, Randomized Study of Gilteritinib and Azacitidine Vs Azacitidine for Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia in Patients Ineligible for Intensive Induction Chemotherapy. Blood (2021) 138 (Supplement 1):700.